US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles
Testimony at Sen. Bob Menendez's bribery trial focuses on his wife's New Jersey home
NEW YORK (AP) — A New Jersey businessman rescued the home of Sen. Bob Menendez’s wife from foreclosu2024-05-22Guyanese president arrives in Chengdu for FISU World University Games
(Xinhua) 13:25, July 27, 2023CHENGDU, July 27 (Xinhua) -- Guyanese President Irfaan Ali on Thursday2024-05-22Egypt to increase number of aid trucks to war
Airdropped humanitarian aid falls toward the Gaza Strip amid the ongoing Israel-Hamas conflict, seen2024-05-22Hamas leader Ismail Haniyeh's 3 sons killed in Israeli raid
Three sons of Ismail Haniyeh, the head of the Hamas Political Bureau, along with his three grandchil2024-05-22Report says China is accelerating the forced urbanization of rural Tibetans
TAIPEI, Taiwan (AP) — An extensive report by Human Rights Watch says China is accelerating the force2024-05-22Nation aims to create over 12 million new jobs
Buoyed by the success of its job promotion last year, China will continue to channel its efforts and2024-05-22
atest comment